# All Wales Management of Refugees at risk of Drug-Resistant Tuberculosis





STEP 1 INFORMATION

Risk of drug-resistant TB

contact of drug-resistant

Assessment

Known household

History of prison

• HIV+, IVDU or Hep C+

 Failure to complete previous TB treatment

#### DID YOU KNOW?

Ukraine has one of the highest rates of Multi Drug-Resistant Tuberculosis in the world.

The humanitarian crisis in Ukraine has prompted the arrival of refugees into the UK, resulting in an impending public health situation.

Find out more from the TB clinical lead for Wales

**STEP 2 INFORMATION** 

INVESTIGATE

BBV Test

HCV antibody

HIV test

• Hep B sAg



Current version: 1.2

#### CORE PRINCIPLES

Asylum seekers and refugees are at high-risk of reactivation of Tuberculosis. Early screening, particularly to detect active TB, is vital to exclude ongoing transmission and ensure treatment success.

Assessment and management should be delivered by designated TB teams within each health board.

#### STEP 1: ASSESSMENT

#### Symptom checklist

- ☑ Cough
- ☑ Fever
- Weight loss
- Night sweats

#### History checklist

- Past history of TB (especially recent treatment interruption due to conflict)?
- ☑ BCG vaccination status?
- ✓ Risk of drug-resistant TB? (1)
- ✓ Nutritional status?
- ✓ Immunosuppression?

#### STEP 2: INVESTIGATE (all patients)

#### Age <11years

If asymptomatic, no investigations

Only screen if symptomatic or if positive parent/ close contact

#### Age ≥11 years, or <11 years with symptoms

Bloods (IGRA, BBV , LFT, FBC, Vit D) and Chest x-ray (in pregnancy, avoid CXR unless symptomatic)

#### **STEP 3: MANAGE**

IGRA or TST (-ve) and Normal CXR and asymptomatic

INFORM AND ADVISE DISCHARGE

IGRA or TST (+ve) and Normal CXR and asymptomatic

### CONSIDER LATENT TB

Initiate 3-months Rifampicin and Isoniazid unless contact of drug resistant TB IGRA or TST (+ve) and Normal CXR and symptomatic

#### CONSIDER NON-PULMONARY ACTIVE TB

Urgent clinical review by TB service and further investigations (samples for TB culture) Abnormal CXR with/without symptoms

## INVESTIGATE FOR ACTIVE TB

Send 2x Sputa for TB smear, PCR (using code UKR2022) and culture to determine sensitivity to Rifampicin

# MANAGE • LATENT TB INFECTION

**STEP 3 INFORMATION** 

Inform and advise patient

Collect sputum if

productive

Initiate 3-months Rifampicin and Isoniazid unless contact of drug resistant TB

Follow-up every 6 months for 2 years

#### TB IN CHILDREN

Make every effort to get a microbiological specimen in children

Babies need to be seen by a specialist as a matter of urgency

Please discuss any patients <1 dyrs who are being investigated for Active TB with paediatric ID in UHW, or the tertiary ID services in Alder Hey (in BCUHB)

Find out more about TB in children here



Determine drug sensitivity

#### RIFAMPICIN SENSITIVE

Start standard WHO Quadruple therapy

Wait for full sensitivities

Admit to local hospital as appropriate

Discuss in MDT if concerns

#### RIFAMPICIN RESISTANT

Assume MDR/XDR-TB

Refer to hospital with negative pressure rooms

Inform Public Health

Follow WHO Guidelines

BBV: Blood borne virus screen
 CXR: Chest x-ray
 ID: Infectious diseases
 IGRA: Intraferon Gamma Release Assay

LTBI: Latent TB infection
MDR: Multi-drug resistant
TST: Tuberculin Skin Test

TST: Tuberculin Skin Test

XDR: Extensively-drug resistant